Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer
New test uses patient's blood sample to detect KRAS, predictive biomarker for solid tumor cancers
KRAS mutations occur in approximately 40% of patients with colorectal cancer, and have been identified in high frequency in lung, pancreatic and other solid tumor cancers. Mutations in the KRAS gene have been shown to be predictive to resistance to anti-EGFR monoclonal antibodies, such as Vectibix® (panitumumab) from Amgen Inc. and Erbitux® (cetuximab) from Eli Lilly and Company.
"Understanding a patient's KRAS status is required to prequalify
that patient for specific antibody-based targeted therapies," said
"Patients with solid tumor cancers such as lung, colorectal and
pancreatic can exhibit few symptoms until the disease reaches an
advanced stage," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to improvement of diagnosis
outcomes and monitoring of patients, the pediatric nature of the KRAS
gene, our impact on diagnostic strategies and planned future offerings,
such statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous
risk factors as set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150805005550/en/
Investor Contact:
LHA
310-691-7100
jcain@lhai.com
Source:
News Provided by Acquire Media